| Revenue Growth | U.S. revenue up 14% ($970M); International revenue up 5% ($375M). |
|---|---|
| Mgmt Confidence | Extremely confident in Long Range Plan; tracking to record new patient year. |
| Demand Visibility | Global new-patient starts near-record levels; active base growth in upper teens. |
| Margin Trends | Gross margin 65.1%, up 380 bps; EBITDA margin 32.4%. |
| Op. Leverage | Operating margin 25.3%; leverage achieved excluding Ireland facility startup costs. |
| Pricing Power | Stable pricing globally; PBM loss expected to be offset by higher pricing. |
| Vol vs Price | Growth driven by record volume/new starts; pricing environment remains stable. |
| Segment Growth | Type 2 non-insulin segment seeing largest share gains in U.S. |
| New Clients | Acquiring European distributor to go direct; record new patient starts. |
| Capex & Debt | Completed $1B share repurchase; new $1B authorization; Ireland facility commercial production. |
| Regulatory | Awaiting CMS Type 2 non-insulin coverage decision expected by year-end 2026. |
| Commentary | Focusing on 'Dexcom Direct' to bypass PBM restrictions and maintain access. |
| New Launches | Stellow app redesign; G7 15-day system; Canada launch November 2026. |
Growth
Worldwide revenue grew 11% to $1.34B; U.S. revenue grew 14% to $970M.
Outlook
Raised 2026 revenue guidance to $5.20B-$5.25B (12-13% growth); targeting 24% operating margin.
Risks
CVS PBM contract loss affecting <4% of U.S. revenue; management used vague 'remuneration' language regarding pricing.
The company's earnings call, NASDAQ: DXCM, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Dexcom Inc: key numbers
- Share price
- $81.61Close, Nov 16
- Market cap
- $30.4B
- Shares outstanding
- 372.95MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dexcom Inc
All →Dexcom Q3 2026 Results: Net Income $275M, Down 3.1% YoY
DexCom reported revenue of $1.34 billion for the third quarter of 2026, representing growth over the $1.21 billion reported in the prior year period. Net income for the nine months ended September 30, 2026, increased to $723.7 million compared to $569.0 million in 2025, driven by higher gross profits and operating income.
- Key figure
- Net income $275M · -3.1% YoY
Dexcom Financial Results
Dexcom reported Q3 2026 revenue of $1.34 billion, representing 11% year-over-year growth, and raised its full-year 2026 revenue guidance to $5.20-$5.25 billion. Alongside the results, the company announced that its Board of Directors authorized a new $1.0 billion share repurchase program effective through December 31, 2027.
“This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives. This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day.”
Jake Leach, Dexcom’s president and CEO
Dexcom EVP Chief People & Culture Off Sadie Stern Sells $202K of Stock
Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $78.62 a share, worth $202K in total on Oct 27, 2026. Shares held after the trade: 120,913 (-2.1%).
- Value
- $202K
- Shares
- 2,565
- Price
- $78.62
- Role
- EVP Chief People & Culture Off
- Holding change
- -2.1%
- Trade date
- Oct 27, 2026
Dexcom EVP Chief Legal Compliance Off Michael Jon Brown Sells $145K of Stock
Michael Jon Brown, EVP Chief Legal Compliance Off, sold 1,700 shares of Dexcom Inc at $85.48 a share, worth $145K in total on Oct 15, 2026. Shares held after the trade: 98,185 (-1.7%).
- Value
- $145K
- Shares
- 1,700
- Price
- $85.48
- Role
- EVP Chief Legal Compliance Off
- Holding change
- -1.7%
- Trade date
- Oct 15, 2026
Dexcom EVP Chief People & Culture Off Sadie Stern Sells $221K of Stock
Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $86.15 a share, worth $221K in total on Sep 28, 2026. Shares held after the trade: 123,478 (-2.0%).
- Value
- $221K
- Shares
- 2,565
- Price
- $86.15
- Role
- EVP Chief People & Culture Off
- Holding change
- -2.0%
- Trade date
- Sep 28, 2026
Dexcom Insider Nicholas Augustinos Sells $680K of Stock
Nicholas Augustinos sold 8,089 shares of Dexcom Inc at $84.02 to $84.04 a share (average $84.04) in 2 transactions, worth $680K in total between Sep 14, 2026 and Sep 15, 2026. Shares held after the trade: 29,293 (-18.2%).
- Value
- $680K
- Shares
- 8,089
- Average price
- $84.04
- Holding change
- -18.2%
- Trade date
- Sep 14, 2026 to Sep 15, 2026